Empowering Sarcoma Patients through Treatment and Resources

As is sure to be demonstrated at this year’s American Society of Clinical Oncology (ASCO) annual meeting, advancements in oncology research and clinical care are changing the way doctors approach cancer treatment. This is especially true for people living with rare cancers such as soft tissue sarcoma (STS).

Lilly made a steadfast commitment to empowering people living with STS to understand their resources and treatment options available. Unfortunately, nearly 13,000 people a year in the U.S. are diagnosed with this rare cancer, and more than 5,000 individuals will die of the disease this year. To address this unmet need, we developed the first human monoclonal antibody approved by the FDA to treat patients with STS, also the first in over 40 years to extend survival when compared to a first-line standard of care. We continue to investigate its use in combination with other STS treatments, with the goal of making life better for even more patients with this rare cancer.

Due to its rarity and complexity, STS is often mistaken for other diseases, and the road to receiving an accurate diagnosis can be long and complicated. Additionally, people often find it difficult to locate relevant and accurate information, and to identify the specialists who know how to treat these rare cancers.

To this end, we’re committed to continuing collaborations with patient advocacy organizations including the Sarcoma Foundation of America and the Sarcoma Alliance. That will bring solutions and support so that patients and their loved ones are empowered to have early and informed conversations with their doctors.